This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00027162%3A_____%2F10%3A%230000612%21RIV11-MZE-00027162/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00027162%3A_____%2F10%3A%230000612%21RIV11-MZE-00027162
rdf:type
skos:Concept n12:Vysledek
dcterms:description
Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100 mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models. Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially preparation of PTX is associated with hypersensitivity reactions. The developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC lipids (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size of 180-190 nm with zeta-potential of -31 mV. Sucrose (lipid/sugar molar ratio, 1:5-10) was found to preserve physical stability of PTX liposomes. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100 mg/kg as a single dose and 150 mg/kg as a cumulative dose applied in 3 equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models.
dcterms:title
Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect
skos:prefLabel
Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect Liposomes With High Encapsulation Capacity for Paclitaxel: Preparation, Characterisation and In Vivo Anticancer Effect
skos:notation
RIV/00027162:_____/10:#0000612!RIV11-MZE-00027162
n3:aktivita
n15:Z
n3:aktivity
Z(MZE0002716202)
n3:cisloPeriodika
5
n3:dodaniDat
n6:2011
n3:domaciTvurceVysledku
n8:5022533 n8:5467489 n8:9373632 n8:9358226 n8:7911939 n8:1858955 n8:8598398 n8:1077392
n3:druhVysledku
n9:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
268613
n3:idVysledku
RIV/00027162:_____/10:#0000612
n3:jazykVysledku
n7:eng
n3:klicovaSlova
B16F10; extrusion; hollow fibre implants; liposomes; lyophilisation; melanoma; nanotechnology; paclitaxel; particle size; stability
n3:klicoveSlovo
n5:melanoma n5:nanotechnology n5:lyophilisation n5:extrusion n5:stability n5:hollow%20fibre%20implants n5:B16F10 n5:particle%20size n5:liposomes n5:paclitaxel
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[836C411E3817]
n3:nazevZdroje
Journal of Pharmaceutical Sciences
n3:obor
n16:FR
n3:pocetDomacichTvurcuVysledku
8
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n6:2010
n3:svazekPeriodika
99
n3:tvurceVysledku
Korvasová, Zina Mašek, Josef Turánek, Jaroslav Plocková, Jana Škrabalová, Michaela Turánek-Knötigová, Pavlína Koudelka, Štěpán Bartheldyová, Eliška
n3:wos
000277132500009
n3:zamer
n13:MZE0002716202
s:issn
0022-3549
s:numberOfPages
11